H3N2 News and Research RSS Feed - H3N2 News and Research

Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings. [More]
Simple tips to keep families safe from flu

Simple tips to keep families safe from flu

The flu, or seasonal influenza virus, is extremely unpredictable. Its severity can vary widely from one season to the next depending on many things, including the strains of flu spreading, availability of vaccines, how many people get vaccinated and how well the flu vaccine is matched to the flu viruses circulating each season. [More]
Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter. [More]
Study shows seasonal flu vaccines may protect individuals against many different viruses

Study shows seasonal flu vaccines may protect individuals against many different viruses

Seasonal flu vaccines may protect individuals not only against the strains of flu they contain but also against many additional types, according to a study published this week in mBio, the online open-access journal of the American Society for Microbiology. [More]
FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. [More]
CDC urges all adults to get flu vaccination

CDC urges all adults to get flu vaccination

Influenza vaccination coverage estimates show an encouraging upward trend overall, but coverage among healthy 18 to 64 year-olds has yet to top 40 percent, according to new data announced at a news conference held today by the National Foundation for Infectious Diseases. [More]
Getting flu shot every autumn can lead to better health

Getting flu shot every autumn can lead to better health

Everyone knows that the best way to avoid the flu is by getting an annual flu shot. But a trip to your physician every autumn for the vaccination can help you avoid much more than the dreaded flu bug. "At the doctor's office, the focus is on you and what is going on with your health. This is your time to talk about concerns to improve your well-being beyond the flu season," says Jorge Parada, MD, MPH, the medical director of the Infection Prevention and Control Program at Loyola University Health System. [More]
Avian influenza A H3N8 virus poses threat to humans

Avian influenza A H3N8 virus poses threat to humans

A study led by St. Jude Children's Research Hospital scientists found the avian influenza A H3N8 virus that killed harbor seals along the New England coast can spread through respiratory droplets and poses a threat to humans. [More]
CDC report reveals that younger age group is mostly hit by flu this season

CDC report reveals that younger age group is mostly hit by flu this season

This influenza season was particularly hard on younger- and middle-age adults, the Centers for Disease Control and Prevention reported in today's Morbidity and Mortality Weekly Report. [More]
Researchers show for first time how influenza A viruses infect respiratory cells

Researchers show for first time how influenza A viruses infect respiratory cells

Researchers at the University of California, San Diego School of Medicine have shown for the first time how influenza A viruses snip through a protective mucus net to both infect respiratory cells and later cut their way out to infect other cells. [More]
European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

A study led by St. Jude Children's Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology. [More]
Emerging H7N9 virus has potential to cause a pandemic

Emerging H7N9 virus has potential to cause a pandemic

A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts. [More]
Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4 years of age and older, and Flucelvax (Influenza Virus Vaccine), approved for use in adults 18 years of age and older. [More]
NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates. [More]
First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24. [More]
Seattle researchers map critical molecules that regulate inflammation during flu infection

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection. [More]
NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
iBio announces production of vaccine candidate for new H7N9 influenza virus

iBio announces production of vaccine candidate for new H7N9 influenza virus

iBio, Inc. today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch platform. [More]